Listed

PharmaCyte Biotech, Inc.: Form 10-K for the period ended Apr 30, 2015

Filed with the SEC on Jul 29, 2015 and accepted by EDGAR at Jul 29, 2015, 16:02 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-04-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2015-02-01 to 2015-04-30$0us-gaap:Revenues
Revenue12 months2014-05-01 to 2015-04-30$0us-gaap:Revenues
Cost of revenue3 months2015-02-01 to 2015-04-30$0us-gaap:CostOfRevenue
Cost of revenue12 months2014-05-01 to 2015-04-30$0us-gaap:CostOfRevenue
Gross profit3 months2015-02-01 to 2015-04-30$0us-gaap:GrossProfit
Gross profit12 months2014-05-01 to 2015-04-30$0us-gaap:GrossProfit
Research and development12 months2014-05-01 to 2015-04-30$3.5mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2014-05-01 to 2015-04-30−$13.7mus-gaap:OperatingIncomeLoss
Interest expense12 months2014-05-01 to 2015-04-30$4.9kus-gaap:InterestExpense
Income tax12 months2014-05-01 to 2015-04-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2015-02-01 to 2015-04-30−$4.9mus-gaap:NetIncomeLoss
Net income12 months2014-05-01 to 2015-04-30−$10.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2015-02-01 to 2015-04-30−$0.01us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS12 months2014-05-01 to 2015-04-30−$0.02us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)12 months2014-05-01 to 2015-04-30704,327,656 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2014-05-01 to 2015-04-30−$4.6mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash and equivalentsAt period end2015-04-30$2.7mus-gaap:Cash
Current assetsAt period end2015-04-30$2.8mus-gaap:AssetsCurrent
Total assetsAt period end2015-04-30$7.9mus-gaap:Assets
Current liabilitiesAt period end2015-04-30$2.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2015-04-30$2.0mus-gaap:Liabilities
Shareholders' equityAt period end2015-04-30$5.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001019687-15-002894. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.